← Back
NeuroTrials.ai
Neurology Clinical Trial Database

HeadPoST

Cluster-Randomized, Crossover Trial of Head Positioning in Acute Stroke

Year of Publication: 2017

Authors: Anderson CS, Arima H, Lavados P, et al. (HeadPoST Investigators and Coordinators)

Journal: NEJM

Citation: N Engl J Med 2017;376:2437–2447. DOI: 10.1056/NEJMoa1615715

Link: https://doi.org/10.1056/NEJMoa1615715

Bottom Line

Head positioning (lying-flat vs sitting-up ≥30°) initiated a median of 14 hours after acute stroke onset and maintained for 24 hours did not alter 90-day disability, mortality, or pneumonia risk.

Major Points

  • Pragmatic international cluster-randomized crossover trial at 114 hospitals in 9 countries randomized 11,093 acute-stroke patients (5,295 lying-flat vs 5,798 sitting-up) to a head position initiated soon after admission and maintained for 24 hours.
  • Primary outcome (90-day disability on modified Rankin scale) showed no difference: unadjusted OR 1.01 (95% CI 0.92–1.10), P=0.84; adjusted analyses and analyses restricted to ischemic stroke or ICH gave the same result.
  • Death or major disability (mRS 3–6) at 90 days: 38.9% vs 39.7% (OR 0.94, 95% CI 0.85–1.05, P=0.25); 90-day mortality 7.3% vs 7.4% (OR 0.98, 95% CI 0.85–1.14, P=0.83).
  • Serious adverse events (14.3% vs 13.5%, P=0.51), including pneumonia, did not differ; the sitting-up group achieved better position adherence (95% vs 87% maintained for 24 hours, P<0.001).
  • Findings were consistent across prespecified subgroups (age, sex, region, baseline NIHSS, time from onset, stroke subtype, randomization sequence); most patients were enrolled well beyond the reperfusion window with mostly mild strokes (median NIHSS 4).

Design

Study Type: Pragmatic, cluster-randomized, crossover, open-label trial with blinded outcome assessment

Randomization: 1

Blinding: Open-label intervention; outcome assessors blinded (PROBE-style)

Enrollment Period: March 2, 2015 – November 29, 2016

Follow-up Duration: 90 days

Centers: 114

Countries: Australia, China, Taiwan, India, Sri Lanka, United Kingdom, Chile, Brazil, Colombia

Sample Size: 11093

Analysis: Intention-to-treat, ordinal logistic-regression mixed model with fixed intervention and period effects, random cluster effect, and cluster × period interaction; multiple imputation for missing mRS


Inclusion Criteria

  • Age ≥18 years
  • Clinical diagnosis of acute stroke (ischemic or intracerebral hemorrhage)
  • Presentation to emergency department or inpatient service at a participating hospital
  • Patients with acute intracerebral hemorrhage (but not subarachnoid hemorrhage) purposely included
  • Ability to assume the assigned head position soon after admission

Exclusion Criteria

  • Confirmed diagnosis of transient ischemic attack
  • Clear clinical indication for, or contraindication to, either head position (e.g., patients likely requiring intubation)
  • Local clinician-investigator judged the assigned head position could not be consistently maintained
  • Subarachnoid hemorrhage
  • Patient declined participation

Arms

FieldLying-flatControl
InterventionFully supine (back horizontal, face upwards), initiated soon after admission and maintained for 24 hours, including during eating, drinking, and toiletingHead of bed elevated to ≥30° (confirmed by protractor), maintained for 24 hours; toilet privileges outside bed permitted per mobility
Duration24 hours24 hours

Outcomes

OutcomeTypeControlInterventionHR / OR / RRP-value
Shift in distribution of 90-day disability on the modified Rankin scale (mRS 0–6), analyzed by ordinal logistic regressionPrimarySitting-up mRS distribution (reference)Lying-flat mRS distribution1.010.84
Death or major disability (mRS 3–6) at 90 daysSecondary39.7%38.9%0.940.25
All-cause death within 90 daysSecondary7.4%7.3%0.980.83
EQ-5D visual-analogue self-rated health at 90 daysSecondaryreferencefavored lying-flat0.009
Position adherence (maintained assigned position for 24 h)Secondary95%87%<0.001
Premature cessation of assigned position within 24 hSecondary4.2%13.0%<0.001
mRS distribution at 7 days / NIHSS categorical scores at 7 daysSecondaryreferenceno significant differenceNS
Serious adverse events (any)AdverseLying-flat 14.3% vs Sitting-up 13.5% (P=0.51)
PneumoniaAdverseNo significant between-group difference
Cardiopulmonary adverse events / oxygen saturation / blood pressureAdverseNo significant between-group differences

Subgroup Analysis

No significant heterogeneity in the primary outcome across prespecified subgroups defined by age, sex, country/region grouping, baseline NIHSS, time from stroke onset to intervention, major pathologic subtype (ischemic vs ICH), or hospital randomization sequence. Post-hoc analyses by NIHSS quintile and by time-to-intervention quintile also showed no heterogeneity.


Criticisms

  • Median 14 hours from stroke onset to positioning meant most patients were past the reperfusion window and any effect of positioning on the ischemic penumbra would be minimal.
  • Mostly mild strokes (median baseline NIHSS 4), limiting the ability to detect a benefit that might exist in more severe or large-vessel occlusion strokes.
  • Cluster-randomized crossover design with unavoidable open-label intervention; adherence to the lying-flat position was significantly lower (87% vs 95%), potentially diluting a true effect.
  • Target sample size (12,000) not reached; power reestimated using observed intracluster (0.083) and interperiod (0.076) correlations, but subgroup analyses remained underpowered.
  • Included acute intracerebral hemorrhage in a stroke-positioning trial, which mixes pathophysiologies; separate analyses by subtype were nonetheless consistent with the primary result.
  • Enrollment concentrated in centers largely outside the acute reperfusion era limits generalizability to modern thrombolysis/thrombectomy workflows.

Funding

National Health and Medical Research Council of Australia (research grant 1066966); coordinated by the George Institute for Global Health.

Based on: HeadPoST (NEJM, 2017)

Authors: Anderson CS, Arima H, Lavados P, et al. (HeadPoST Investigators and Coordinators)

Citation: N Engl J Med 2017;376:2437–2447. DOI: 10.1056/NEJMoa1615715

Content summarized and formatted by NeuroTrials.ai.